Genesystem secures $20 mil. contract linked to India’s TB eradication effort

Genesystem, a Korean medical device maker, said it has secured a major contract with Genetix Biotech Asia, an Indian life science firm, to construct a local diagnostic kit production facility, and supply diagnostic equipment, test kits, and consumables related to tuberculosis (TB).

The company plans to initially supply some components and raw material from its Korean plant and then move manufacturing to India after the local production facility is completed.

The contract is worth $20 million (29.3 billion won) with a completion date set for March 28, 2027, marking the largest deal in the company’s history.

According to Genesystem, India accounts for the highest number of TB cases globally, representing about 25 percent of the global burden, according to the World Health Organization (WHO). Recognizing TB as a critical public health issue, the Indian government extended its TB eradication program from 2025 to 2027 and is intensifying its efforts in diagnosis and treatment.

The company expressed optimism about the possibility of additional contracts as it receives approval for new diagnostic kits, such as hepatitis B and C and human immunodeficiency virus (HIV).

Genesystem has also been working closely with Genetix Biotech to obtain approvals from international health organizations, including WHO, the Foundation for Innovative New Diagnostics (FIND), and the Feasibility of Novel Diagnostics (FEND).

Once approvals are secured, Genesystem anticipates that its Indian production facility will play as its front operating base in going global.

“With this agreement signals we aim to play a central role in India’s TB eradication program,” a Genesystem spokesperson said. “Going forward, we plan to work with various countries and global organizations to address pressing public health challenges worldwide.”